Active, Not Recruiting
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors - CA047-004
Atualizado: 9 fevereiro, 2024 | ClinicalTrials.gov
Fase
Gênero(s)
Faixa etária
Active, Not Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1 - Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor - Eastern cooperative oncology group performance status of 0 or 1 - Men and women must agree to follow methods of contraception Exclusion Criteria: - Participants with active, known or suspected autoimmune disease - Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications - Uncontrolled or significant cardiovascular disease - History of or with active interstitial lung disease or pulmonary fibrosis - Prior participation in anti-NKG2A clinical study - History of allergy or hypersensitivity to study drug components Other protocol-defined inclusion/exclusion criteria apply
É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas
